专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明授权

US08618251B1 Fc mutants 有权
标题翻译： Fc突变体
公开(公告)号：US08618251B1
公开(公告)日：2013-12-31
申请号：US12942824
申请日：2010-11-09
申请人： Jeffrey V. Ravetch , Rene G. Ott
发明人： Jeffrey V. Ravetch , Rene G. Ott
IPC分类号： C07K1/00 , C07K16/00 , C12P21/08 , C07K17/00
CPC分类号： C07K16/2803 , A61K39/00 , G01N21/59
摘要： The present invention provides reagents, methods and systems for predicting the inhibitory activity of an antibody or variant thereof comprising: determining a binding affinity of the antibody or variant thereof to a Fc activating receptor; determining a binding affinity of the antibody or variant thereof to a Fc inhibitory receptor, and calculating the ratio of said activating binding affinity to said inhibitory binding affinity (A/I ratio), wherein the magnitude of said ratio is less than one (1).
摘要翻译：本发明提供了用于预测抗体或其变体的抑制活性的试剂，方法和系统，其包括：测定抗体或其变体与Fc激活受体的结合亲和力; 测定抗体或其变体对Fc抑制受体的结合亲和力，并计算所述活化结合亲和力与所述抑制性结合亲和力（A / I比）的比例，其中所述比例的量值小于1（1）。

62. 发明授权

US08586051B2 Glycolipids and analogues thereof as antigens for NKT cells 有权
标题翻译：糖脂及其类似物作为NKT细胞的抗原
公开(公告)号：US08586051B2
公开(公告)日：2013-11-19
申请号：US13420738
申请日：2012-03-15
申请人： Moriya Tsuji , David D. Ho , Chi-Huey Wong , Douglass Wu , Masakazu Fujio , Xiangming Li
发明人： Moriya Tsuji , David D. Ho , Chi-Huey Wong , Douglass Wu , Masakazu Fujio , Xiangming Li
IPC分类号： A61K39/00
CPC分类号： C07H15/04 , A61K39/39 , C07H15/10
摘要： This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
摘要翻译：本发明涉及用作NKT（天然杀伤T）细胞的配体的免疫原性化合物及其在调节免疫应答中的应用。

63. 发明申请

US20130244325A1 MITOCHONDRIAL TARGETED STIMULATORS OF APOPTOSIS 有权
标题翻译：麻醉靶向刺激因子
公开(公告)号：US20130244325A1
公开(公告)日：2013-09-19
申请号：US13611128
申请日：2012-09-12
申请人： Hermann STELLER , Cristinel SANDU , Anshuman KELKAR , Nidhi GANGADHAR
发明人： Hermann STELLER , Cristinel SANDU , Anshuman KELKAR , Nidhi GANGADHAR
IPC分类号： C07D401/14 , C07D303/40 , C07D303/46
CPC分类号： C07D401/14 , C07D303/40 , C07D303/46 , C07D405/14 , C07D413/14
摘要： Pro-apoptotic compounds having a tripartite structure: A-L-B are disclosed. In these compounds A is an IBM mimetic moiety; L is a linker and B is a moiety that binds to a protein on the outer mitochondrial membrane. The compounds are useful for inducing cell apoptosis and therefore treating cancer. An example of such a compound is
摘要翻译：公开了具有三方结构的促凋亡化合物：A-L-B。在这些化合物中，A是IBM模拟部分; L是接头，B是结合外线粒体膜上的蛋白质的部分。该化合物可用于诱导细胞凋亡并因此治疗癌症。这种化合物的例子是

64. 发明申请

US20130225491A1 Methods and Kits for Treating Disease By Administering Insulin-Like Growth Factor Binding Protein-2 审中-公开
标题翻译：通过管理胰岛素样生长因子结合蛋白-2治疗疾病的方法和试剂盒
公开(公告)号：US20130225491A1
公开(公告)日：2013-08-29
申请号：US13766373
申请日：2013-02-13
申请人： The Rockefeller University
发明人： Jeffrey Friedman , Kristina Hedbacker
IPC分类号： A61K38/17
CPC分类号： A61K38/1754
摘要： The present invention is directed to methods of treating Type 1-diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods treating Type 2 diabetes by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is further directed to methods treating insulin resistance by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is directed to methods of treating hepatic steatosis by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods lowering blood glucose and serum insulin in non-diabetic subjects by administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2.
摘要翻译：本发明涉及通过施用治疗有效量的胰岛素样生长因子结合蛋白-2来治疗1型糖尿病的方法。本发明还涉及通过施用治疗有效量的胰岛素样生长因子结合蛋白-2来治疗2型糖尿病的方法。本发明还涉及通过施用治疗有效量的胰岛素样生长因子结合蛋白-2来治疗胰岛素抵抗的方法。本发明涉及通过施用治疗有效量的胰岛素样生长因子结合蛋白-2来治疗肝脂肪变性的方法。本发明还涉及通过施用治疗有效量的胰岛素样生长因子结合蛋白-2来降低非糖尿病受试者的血糖和血清胰岛素的方法。

65. 发明授权

US08399628B2 Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same and methods of use thereof 有权
公开(公告)号：US08399628B2
公开(公告)日：2013-03-19
申请号：US12840967
申请日：2010-07-21
申请人： Yongwon Choi , Brian Wong , Regis Josien , Ralph Steinman
发明人： Yongwon Choi , Brian Wong , Regis Josien , Ralph Steinman
IPC分类号： C07K16/24
CPC分类号： C07K16/2875 , A61K38/00 , A61K39/00 , A61K48/00 , C07K14/525 , C07K14/70575 , C07K2317/76 , C07K2319/30 , C12N15/1096
摘要： A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting the mature dendritic cells ex vivo with a modulator comprising TRANCE, conservative variants thereof, fragments thereof, analogs or derivatives thereof, or a fusion protein comprising the amino acid sequence of TRANCE, conservative variants thereof, or fragments thereof. After contacting the modulator ex vivo, the mature dendritic cells are introduced into the animal. As a result, immune response in the animal towards the antigen is modulated relative to the immune response against the antigen in an animal in which dendritic cells did not interact with the antigen ex vivo, and did not contact a modulator ex vivo. Preferably, the method of the present invention results in increasing immune response towards the antigen in the animal.

66. 发明申请

US20130064813A1 Protein Belonging to the TNF Superfamily Involved in Signal Transduction, Nucleic Acids Encoding Same and Methods of Use Thereof 有权
公开(公告)号：US20130064813A1
公开(公告)日：2013-03-14
申请号：US13586514
申请日：2012-08-15
申请人： Yongwon Choi , Brian Wong , Regis Josien , Ralph Steinman
发明人： Yongwon Choi , Brian Wong , Regis Josien , Ralph Steinman
IPC分类号： A61K39/395 , A61P37/02
CPC分类号： C07K16/2875 , A61K38/00 , A61K39/00 , A61K48/00 , C07K14/525 , C07K14/70575 , C07K2317/76 , C07K2319/30 , C12N15/1096
摘要： A method of modulating immune response in an animal is disclosed. Such a method interacting the immature dendritic cells from the animal with an antigen ex vivo so that the immature dendritic cells present the antigen on their surfaces, inducing maturation of the immature dendritic cells ex vivo, and contacting the mature dendritic cells ex vivo with a modulator comprising TRANCE, conservative variants thereof, fragments thereof, analogs or derivatives thereof, or a fusion protein comprising the amino acid sequence of TRANCE, conservative variants thereof, or fragments thereof. After contacting the modulator ex vivo, the mature dendritic cells are introduced into the animal. As a result, immune response in the animal towards the antigen is modulated relative to the immune response against the antigen in an animal in which dendritic cells did not interact with the antigen ex vivo, and did not contact a modulator ex vivo. Preferably, the method of the present invention results in increasing immune response towards the antigen in the animal.

67. 发明申请

US20130045211A1 METHODS AND COMPOSITIONS FOR ENHANCED IMMUNOLOGICAL THERAPY AND TARGETING OF GRAM-POSITIVE BACTERIA 有权
标题翻译：增强免疫治疗方法和组合物和靶向细菌的靶向
公开(公告)号：US20130045211A1
公开(公告)日：2013-02-21
申请号：US13520601
申请日：2011-01-05
申请人： Robert C. Nowinski , Vincent A. Fischetti , Assaf Raz
发明人： Robert C. Nowinski , Vincent A. Fischetti , Assaf Raz
IPC分类号： A61K39/40 , A01P1/00 , A61P31/04 , A01N37/18 , G01N33/569
CPC分类号： C12N9/52 , A61K31/43 , A61K39/40 , A61K2039/505 , C07K16/1271 , A61K2300/00
摘要： The present invention relates to methods and compositions for use in modulating, including inhibiting the growth and/or reducing the virulence of gram-positive bacteria. The present invention provides methods and compositions for disrupting the cell wall and/or cell membrane in gram-positive bacteria such that cell wall or cell membrane target(s) are rendered exposed or accessible and sensitive to a modulation thereof. Methods for modulation of one or more gram-positive bacterial cell wall or cell membrane targets in a gram-positive bacteria are provided comprising disrupting the cell wall such that the cell wall or cell membrane target, which is particularly a sortase, is rendered exposed or accessible and sensitive to a modifying, modulating or binding agent, which is particularly an antibody or fragment thereof, wherein the cell wall or cell membrane target is inaccessible or relatively insensitive to the modifying, modulating or binding agent in the absence of cell wall disruption.
摘要翻译：本发明涉及用于调节，包括抑制生长和/或降低革兰氏阳性菌的毒力的方法和组合物。本发明提供用于破坏革兰氏阳性细菌中的细胞壁和/或细胞膜的方法和组合物，使得细胞壁或细胞膜靶被暴露或可接近并且对其调节敏感。提供了用于调节革兰氏阳性细菌中一种或多种革兰氏阳性细菌细胞壁或细胞膜靶的方法，包括破坏细胞壁，使得特别是分选酶的细胞壁或细胞膜靶被暴露或对于特别是抗体或其片段的修饰，调节或结合试剂是敏感的，其中细胞壁或细胞膜靶在不存在细胞壁破坏的情况下是不可接近的或对修饰，调节或结合剂相对不敏感的。

68. 发明授权

US08163290B2 Glycolipids and analogues thereof as antigens for NKT cells 有权
标题翻译：糖脂及其类似物作为NKT细胞的抗原
公开(公告)号：US08163290B2
公开(公告)日：2012-04-24
申请号：US12958996
申请日：2010-12-02
申请人： Moriya Tsuji , David D. Ho , Chi-Huey Wong , Douglass Wu , Masakazu Fujio , Xiangming Li
发明人： Moriya Tsuji , David D. Ho , Chi-Huey Wong , Douglass Wu , Masakazu Fujio , Xiangming Li
IPC分类号： A61K39/00
CPC分类号： C07H15/04 , A61K39/39 , C07H15/10
摘要： This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses.
摘要翻译：本发明涉及用作NKT（天然杀伤T）细胞的配体的免疫原性化合物及其在调节免疫应答中的应用。

69. 发明申请

US20120034616A1 Method for Modulating Epithelial Stem Cell Lineage 审中-公开
标题翻译：调节上皮干细胞谱系的方法
公开(公告)号：US20120034616A1
公开(公告)日：2012-02-09
申请号：US12894720
申请日：2010-09-30
申请人： Elaine Fuchs , Colin Jamora , Charles K. Kaufman , Krzysztof Kobielak
发明人： Elaine Fuchs , Colin Jamora , Charles K. Kaufman , Krzysztof Kobielak
IPC分类号： C12Q1/68 , G01N33/566 , C12N5/071
CPC分类号： A61K38/1709 , A61K8/99 , A61K38/18 , A61K2800/86 , A61Q7/00 , A61Q7/02 , G01N33/5044 , A61K2300/00
摘要： The present invention relates to methods of modulating epithelial stem cell lineage by regulating the expression of Lef1 or a BMP inhibitor and/or the stability of β-catenin or the expression of a Wnt; regulating the expression or activity of GATA-3; or regulating BMPR1A activity either at the level of receptor expression or at the level of pathway activation. Methods of regulating E-cadherin, GATA-3, BMPR1A and HK1-hair keratin and methods of identifying agents which modulate the epithelial stem cell lineage are further provided. Such agents are useful for inhibiting or stimulating inner root sheath development or hair follicle formation.
摘要翻译：本发明涉及通过调节Lef1或BMP抑制剂的表达和/或稳定的β-连环蛋白或Wnt的表达来调节上皮干细胞谱系的方法; 调节GATA-3的表达或活性; 或以受体表达水平或途径活化水平调节BMPR1A活性。进一步提供调节E-钙粘蛋白，GATA-3，BMPR1A和HK1毛发角蛋白的方法和鉴定调节上皮干细胞谱系的药剂的方法。这样的试剂可用于抑制或刺激内根鞘发育或毛囊形成。

70. 发明申请

US20110271356A1 HCV ENTRY FACTOR, OCCLUDIN 有权
标题翻译： HCV进入因子，OCCLUDIN
公开(公告)号：US20110271356A1
公开(公告)日：2011-11-03
申请号：US13122339
申请日：2009-10-01
申请人： Alexander Ploss , Matthew Evans , Charles Rice
发明人： Alexander Ploss , Matthew Evans , Charles Rice
IPC分类号： A01K67/00 , A61K31/7088 , A61P31/14 , C40B30/00 , G01N33/566 , C12Q1/68 , A61K39/395 , A61K38/02
CPC分类号： G01N33/5008 , C07K14/705 , C12N2740/16043 , C12N2770/24211 , G01N33/502 , G01N2333/186 , G01N2500/00
摘要： The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV—susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided.
摘要翻译：人类Occludin蛋白被鉴定为必需的丙型肝炎病毒（HCV）细胞进入因子。闭合素显示使鼠和其他非人类细胞能够感染HCV，并且需要人类细胞的HCV敏感性。还公开了用于抑制HCV感染的相关方法，用于HCV发病机理的转基因动物模型，鉴定预防或减轻HCV与Occludin的相互作用的化合物或药剂的方法以及HCV抑制剂。还提供了可用于鉴定预防或减轻HCV与Occludin相互作用的化合物或试剂的试剂盒和细胞培养组合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式